MEDLIB-L Archives

February 2019, Week 3

MEDLIB-L@LIST.UVM.EDU

Options: Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Gerardo Gutierrez <[log in to unmask]>
Reply To:
Gerardo Gutierrez <[log in to unmask]>
Date:
Sun, 17 Feb 2019 19:55:35 -0600
Content-Type:
text/plain
Parts/Attachments:
text/plain (42 lines)
Clinical effectiveness of a combination of bromhexine and amoxicillin in
lower respiratory tract infection. A randomized controlled trial.
Roa CC Jr
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Roa%20CC%20Jr%5BAuthor%5D&cauthor=true&cauthor_uid=7741782>
1, Dantes RB
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Dantes%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=7741782>
.
Author information <https://www.ncbi.nlm.nih.gov/pubmed/7741782#>
Abstract

A multicenter double-blind randomized trial was performed in 22 teaching
hospitals to compare the clinical effectiveness of the combination of
amoxicillin (CAS 26787-78-0) plus bromhexine (CAS 3572-43-8) versus
amoxicillin alone given 4 times a day for 5 to 7 days in the treatment of
clinically diagnosed community-acquired bacterial lower respiratory tract
infections. 392 adult patients diagnosed clinically to have acute
bronchitis or pneumonia of bacterial etiology were recruited for the study
with 192 subjects given amoxicillin (250 mg) plus bromhexine (8 mg) (Drug
AB) and 200 receiving amoxicillin (250 mg) (Drug AA) alone 4 times a day
for 5 to 7 days. Clinical response, improvement in symptom scores using a
visual analogue scale, and bacteriologic response were monitored at Days 3,
5 and 7 of treatment. Results showed that although 180/192 (94%) given Drug
AB and 185/200 (93%) given Drug AA had favorable clinical response at the
end of treatment, the infection was completely resolved for 89/192 (46%)
among the Drug AB group and in 67/200 (34%) of patients on Drug AA (p =
0.022). Also, patients given Drug AB had significantly greater reduction of
their symptom scores at Day 3 for symptoms of cough discomfort, cough
frequency, ease of expectoration and sputum volume. Among the subset of
patients with pneumonia, the cure rates for Drug AB and Drug AA were 24/50
(47%) and 11/50 (22%), respectively (p = 0.008). A respiratory pathogen was
cultured in only 72/392 (18%) of subjects.(ABSTRACT TRUNCATED AT 250 WORDS).
PMID:7741782
[Indexed for MEDLINE]

REGARDS


GERARDO GTZ
MEDICAL LIBRARIAN EDUFARM

   -

ATOM RSS1 RSS2